ArticleCurrent microbiology2025
Purification and Characterization of Antimicrobial Peptide from an Epilithic Bacterium Streptomyces sp. AL50 with Activity Against Biofilm Forming Coagulase-Negative Staphylococci.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative antimicrobial activity of crude and partially purified Weissella cibaria NM1 postbiotics against Klebsiella pneumoniae ATCC13382.Antonie van Leeuwenhoek · 2026Article
- Antimicrobial Peptides, Bacteriocins and Mycocins as Natural Antimicrobials: Applications in Food Safety, Agriculture and Healthcare.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptide (AMP) is increasingly recognized as a promising new avenue in addressing the challenge of antibiotic resistance, offering a notable alternative to traditional antibiotic molecules. The current research focuses on extracting and characterizing AMP named as AMP1 from epilithic bacterial isolate Streptomyces sp. AL50, an area that has so far remained underexplored. The AMP1 was purified by ammonium sulfate precipitation, dialysis, and sephadex G-100 column chromatography. Subsequent analysis using Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed major band with molecular mass of approximately 10.83 kDa. The peptide demonstrated potent activity against Staphylococcus epidermis MTCC3615, with MIC value of 4 μg/mL. Remarkably, the peptide retained its activity up to 70 °C temperature and within a pH range of 6.0-8.0. However, its activity was abolished by proteinase K, trypsin, and papain, while pepsin, lipase, and α-amylase had no effect. Furthermore, AMP1 displayed notable capabilities in inhibiting and eradicating biofilms. These results indicate that AMP1 hold significant potential as antibiotic candidates for treating multidrug-resistant bacterial infections.
Indexed as
Identifiers
40705114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.